Get the Stockscreener App
2.29
1.78%
0.04
Pre-market:
2.25
-0.04
-1.75%
Context Therapeutics Inc stock is traded at $2.29, with a volume of 376.38K.
It is up +1.78% in the last 24 hours and down -3.38% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$2.25
Open:
$2.2
24h Volume:
376.38K
Relative Volume:
0.26
Market Cap:
$210.40M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-2.5165
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+0.44%
1M Performance:
-3.38%
6M Performance:
+169.48%
1Y Performance:
+158.00%
1-Day Range:
$2.08
$2.32
1-Week Range:
$2.08
$2.54
52-Week Range:
$0.49
$2.85
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.29 | 206.73M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - TipRanks
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan
Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan
What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru
Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru
Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Will AGF A S (5IN) stock return to pre crash levelsQuarterly Growth Report & Smart Swing Trading Alerts - mfd.ru
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
Biotech firm Context Therapeutics lines up four investor conferences - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - Defense World
Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen - Defense World
Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance
THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
TELA Bio Grants Equity to New Hires as Medtech Growth Push Continues - mychesco.com
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
Ideas Watch: How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm
JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Sarepta Therapeutics, Inc. (SRPT) stock: surges after-hours ahead of key Phase 3 results webcast - parameter.io
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com
AI Stocks: Can TRTX deliver consistent dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - baoquankhu1.vn
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):